BBNX Insider Trade: CFO Exercises 9,900 Options and Sells Under 10b5-1
Rhea-AI Filing Summary
Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), exercised employee stock options and completed an offsetting sale on 09/08/2025. He exercised 9,900 options with an exercise/conversion price of $5.10 per share, resulting in acquisition of 9,900 shares underlying the option.
The same day Mr. Feider sold 9,900 shares pursuant to a Rule 10b5-1 plan adopted May 15, 2025, at a weighted average sale price of $21.12648 per share (range $21.00–$21.2933). After these reported transactions he beneficially owned 44,041 shares of common stock and reported 89,695 derivative securities beneficially owned.
Positive
- Sale executed under a Rule 10b5-1 plan, indicating pre-established compliance with insider trading rules
- Options exercised at $5.10 per share, creating realized value when sold at a much higher weighted average price
- Vesting schedule disclosed (48 equal monthly installments from 09/14/2023), providing transparency on option terms
Negative
- Insider sold 9,900 shares, which reduces direct insider ownership from 53,941 to 44,041 shares
- Reported sale price range ($21.00–$21.2933) shows shares were disposed of at market prices, potentially signaling partial liquidity-taking by management
Insights
TL;DR Insider exercised 9,900 options at $5.10 and sold the resulting shares under a 10b5-1 plan at a $21.13 weighted average.
The transaction is a routine exercise-and-sale by a named executive, reducing his direct common stock position from 53,941 to 44,041 shares after the trade. The exercise price of $5.10 and immediate sale at a weighted average of $21.12648 suggests a significant realized gain on the exercise itself. From an investor perspective, this is a liquidity and tax-management event rather than a disclosure of new information about company operations. The use of a pre-established Rule 10b5-1 plan indicates the sale followed an automated compliance framework.
TL;DR Transaction followed a documented 10b5-1 plan and includes option vesting and exercise disclosures, consistent with governance best practices.
The filing discloses vesting terms for the exercised options (48 equal monthly installments from 09/14/2023) and cites a Rule 10b5-1 plan adopted 05/15/2025 for the sale. These disclosures are transparent and align with expected insider-trading controls. The simultaneous exercise and sale should be monitored for timing patterns, but the form shows adherence to procedural guardrails rather than ad hoc insider trading.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 9,900 | $0.00 | -- |
| Exercise | Common Stock | 9,900 | $5.10 | $50K |
| Sale | Common Stock | 9,900 | $21.1264 | $209K |
Footnotes (1)
- Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. The weighted average sale price for the transaction reported was $21.126480 and the range of prices were between $21.00 and $21.2933. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
